论文部分内容阅读
由日本“绿十字”制药公司出资赞助的,世界首次以先进基因疗法治疗艾滋病的大规模临床试验,己由美国生物制品公司于92年度开始。目前,被认为对艾滋病治疗有效的药物主要有AZT等三种,尽管这些药物都是有延续患者生命的作用,但却很难达到完全根治。而本次试验所采用的方法,是把由患者体内取出的细胞基因加以处理,来提高患者的免疫能力,以达到从体内将病毒赶出去,从根本上治疗的目的。其具体做法是:
A large-scale clinical trial funded by Japan’s “Green Cross” pharmaceutical company, which is the first in the world to treat AIDS with advanced gene therapy, was started by American Biological Products Company in the fiscal year of 1992. At present, there are mainly three kinds of drugs that are considered to be effective in AIDS treatment, such as AZT. Although these drugs all have the effect of prolonging the life of patients, it is very difficult to achieve a complete cure. The test used in this method is to take out the patient’s cell genes to be processed to improve the immune capacity of patients in order to get rid of the virus from the body, and ultimately the purpose of treatment. The specific approach is: